[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"toxicity-radiation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:toxicity-radiation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100659227","multicenter-prospective-observational-study-on-prostate-salvage-using-high-dose-rate-brachytherapy-100659227",false,"NCT07860528","Study on Prostate Salvage Using High-dose-rate Brachytherapy","Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy","PROSCATE","Inclusion Criteria:\n\n* Age over 18 years.\n* Patients diagnosed with local recurrence confirmed by next-generation imaging and a positive biopsy.\n* Hormone-sensitive patient.\n* Patients whose initial treatment consisted of brachytherapy alone, external beam radiotherapy, or external beam radiotherapy with a prostate brachytherapy boost.\n\nExclusion Criteria:\n\n* Metastatic disease.\n* Castration-resistant prostate cancer, defined according to EAU (European Association of Urology) guidelines: A patient who progresses despite maintaining testosterone levels within the castration range (testosterone \\\u003C50 ng\u002FdL or \\\u003C1.7 nmol\u002FL) and presents with at least one of the following factors: Three consecutive rises in PSA (Prostate-Specific Antigen) levels, measured one week apart, representing two increases of 50% above the nadir, with a PSA level \\>2; PSA progression despite successive hormonal manipulations; Progression of bone lesions: progression or appearance of two or more bone lesions, or soft-tissue progression according to Response Evaluation Criteria in Solid Tumors (RECIST criteria).","ALL","18 Years",{"count":20,"type":21},63,"ESTIMATED","4 Years","OBSERVATIONAL","A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)\u002Fprostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.",[26,27,28,29,30],"Prostate Cancer","Locally Recurrent Cancer","Biochemically Recurrent Prostate Carcinoma","Toxicity Radiation","Quality of Life",[32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Prostate cancer","Salvage brachytherapy","Local recurrence","Reirradiation","Biochemical relapse-free survival","Local recurrence-free survival","Biochemical recurrence","Acute and chronic toxicity","Quality of life","Choline PET; PSMA PET","MRI","Prostate biopsy","External beam radiotherapy","Brachytherapy boost","Salvage treatment","RECRUITING","2026-10-06",{"date":50,"type":51},"2026-10-09","ACTUAL",{"date":53,"type":51},"2026-03-11",{"date":55,"type":21},"2032-04-30",{"name":57,"class":58},"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","OTHER",10]